{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:32:26Z","timestamp":1787898746949,"version":"build-2784847793"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21907084"],"award-info":[{"award-number":["21907084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773632"],"award-info":[{"award-number":["81773632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LZ19H300001"],"award-info":[{"award-number":["LZ19H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFA0202900"],"award-info":[{"award-number":["2016YFA0202900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2020QNA7003"],"award-info":[{"award-number":["2020QNA7003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.drudis.2021.09.003","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T11:46:16Z","timestamp":1631792776000},"page":"326-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4669-619X","authenticated-orcid":false,"given":"Liu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3014-6719","authenticated-orcid":false,"given":"Xueping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-2580","authenticated-orcid":false,"given":"Tingjun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.09.003_b0005","unstructured":"World Health Organization. Global tuberculosis report 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329368\/9789241565714-eng.pdf"},{"key":"10.1016\/j.drudis.2021.09.003_b0010","unstructured":"World Health Organization. Global tuberculosis report 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336069\/9789240013131-eng.pdf"},{"issue":"8","key":"10.1016\/j.drudis.2021.09.003_b0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline\u2014the benefit\u2013risk balance for drug-resistant tuberculosis","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.09.003_b0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"issue":"16","key":"10.1016\/j.drudis.2021.09.003_b0025","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2021.09.003_b0030","doi-asserted-by":"crossref","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63: e147\u201395. doi:10.1093\/cid\/ciw376","DOI":"10.1093\/cid\/ciw376"},{"key":"10.1016\/j.drudis.2021.09.003_b0035","doi-asserted-by":"crossref","unstructured":"Dulberger CL, Rubin EJ, Boutte CC. The mycobacterial cell envelope\u2014a moving target. Nat Rev Microbiol 2020; 18: 47\u201359. doi:10.1038\/s41579-019-0273-7","DOI":"10.1038\/s41579-019-0273-7"},{"key":"10.1016\/j.drudis.2021.09.003_b0040","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2741\/1291","article-title":"Persistent and dormant tubercle bacilli and latent tuberculosis","volume":"9","author":"Zhang","year":"2004","journal-title":"Front Biosci"},{"issue":"4","key":"10.1016\/j.drudis.2021.09.003_b0045","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/ajt.15841","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020","volume":"20","author":"Sterling","year":"2020","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.drudis.2021.09.003_b0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"9547","key":"10.1016\/j.drudis.2021.09.003_b0055","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","article-title":"Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa","volume":"368","author":"Gandhi","year":"2006","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.drudis.2021.09.003_b0060","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1021\/acs.jmedchem.8b00281","article-title":"Overview of the development of DprE1 inhibitors for combating the menace of tuberculosis","volume":"61","author":"Chikhale","year":"2018","journal-title":"J Med Chem"},{"issue":"W1","key":"10.1016\/j.drudis.2021.09.003_b0065","doi-asserted-by":"crossref","first-page":"W550","DOI":"10.1093\/nar\/gkw393","article-title":"ACFIS: a web server for fragment-based drug discovery","volume":"44","author":"Hao","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.drudis.2021.09.003_b0070","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0014-2016","article-title":"Oxidative phosphorylation as a target space for tuberculosis: success, caution, and future directions","volume":"5","author":"Cook","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"9","key":"10.1016\/j.drudis.2021.09.003_b0075","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2021.09.003_b0080","doi-asserted-by":"crossref","unstructured":"Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223\u20137. doi:10.1126\/science.1106753","DOI":"10.1126\/science.1106753"},{"issue":"11","key":"10.1016\/j.drudis.2021.09.003_b0085","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.bbabio.2011.06.016","article-title":"The cytochrome bd respiratory oxygen reductases","volume":"1807","author":"Borisov","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"28","key":"10.1016\/j.drudis.2021.09.003_b0090","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1073\/pnas.1706139114","article-title":"Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection","volume":"114","author":"Kalia","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0095","article-title":"The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd","volume":"8","author":"Lu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2021.09.003_b0100","doi-asserted-by":"crossref","first-page":"e01275","DOI":"10.1128\/mBio.01275-14","article-title":"A Mycobacterium tuberculosis cytochrome bd oxidase mutant is hypersensitive to bedaquiline","volume":"5","author":"Berney","year":"2014","journal-title":"mBio"},{"issue":"27","key":"10.1016\/j.drudis.2021.09.003_b0105","doi-asserted-by":"crossref","first-page":"12275","DOI":"10.1073\/pnas.1003219107","article-title":"Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice","volume":"107","author":"Dhar","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0110","article-title":"The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0115","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013207","article-title":"Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis","volume":"13","author":"Lee","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11030-020-10034-0","article-title":"Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase","volume":"25","author":"Harikishore","year":"2021","journal-title":"Mol Divers"},{"issue":"41","key":"10.1016\/j.drudis.2021.09.003_b0125","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1021\/bi051282o","article-title":"Mechanisms of product feedback regulation and drug resistance in cytidine triphosphate synthetases from the structure of a CTP-inhibited complex","volume":"44","author":"Endrizzi","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2021.09.003_b0130","doi-asserted-by":"crossref","unstructured":"Mori G, Chiarelli LR, Esposito M, Makarov V, Bellinzoni M, Hartkoorn RC, et al. Thiophenecarboxamide derivatives activated by EthA kill Mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG. Chem Biol 2015; 22: 917\u201327. doi:10.1016\/j.chembiol.2015.05.016","DOI":"10.1016\/j.chembiol.2015.05.016"},{"issue":"6","key":"10.1016\/j.drudis.2021.09.003_b0135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/acsinfecdis.7b00006","article-title":"A phenotypic based target screening approach delivers new antitubercular CTP synthetase inhibitors","volume":"3","author":"Esposito","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2021.09.003_b0140","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1042\/BST20140131","article-title":"Recent advances in targeting coenzyme A biosynthesis and utilization for antimicrobial drug development","volume":"42","author":"Moolman","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.drudis.2021.09.003_b0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mib.2015.10.002","article-title":"Chewing the fat: lipid metabolism and homeostasis during M. tuberculosis infection","volume":"29","author":"Lovewell","year":"2016","journal-title":"Curr Opin Microbiol"},{"issue":"14","key":"10.1016\/j.drudis.2021.09.003_b0150","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1111\/bph.13694","article-title":"Cholesterol metabolism: a potential therapeutic target in mycobacteria","volume":"174","author":"Abuhammad","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1574-6968.12302","article-title":"Mechanism-based inhibition of HsaD: a C-C bond hydrolase essential for survival of Mycobacterium tuberculosis in macrophage","volume":"350","author":"Ryan","year":"2014","journal-title":"FEMS Microbiol Lett"},{"issue":"14","key":"10.1016\/j.drudis.2021.09.003_b0160","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/bph.13810","article-title":"Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach","volume":"174","author":"Ryan","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"23","key":"10.1016\/j.drudis.2021.09.003_b0165","doi-asserted-by":"crossref","first-page":"E5279","DOI":"10.1073\/pnas.1801287115","article-title":"Coordination of the leucine-sensing Rag GTPase cycle by leucyl-tRNA synthetase in the mTORC1 signaling pathway","volume":"115","author":"Lee","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"sup2","key":"10.1016\/j.drudis.2021.09.003_b0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14756366.2016.1190712","article-title":"Identification of Mycobacterium tuberculosis leucyl-tRNA synthetase (LeuRS) inhibitors among the derivatives of 5-phenylamino-2H-[1,2,4]triazin-3-one","volume":"31","author":"Gudzera","year":"2016","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"10.1016\/j.drudis.2021.09.003_b0175","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.bmc.2016.01.028","article-title":"Discovery of potent anti-tuberculosis agents targeting leucyl-tRNA synthetase","volume":"24","author":"Gudzera","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"19","key":"10.1016\/j.drudis.2021.09.003_b0180","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.drudis.2021.09.003_b0185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00240-19","article-title":"First-time-in-human study and prediction of early bactericidal activity for GSK3036656, a potent leucyl-tRNA synthetase inhibitor for tuberculosis treatment","volume":"63","author":"Tenero","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.drudis.2021.09.003_b0190","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10822-019-00245-5","article-title":"Dual-targeted hit identification using pharmacophore screening","volume":"33","author":"Volynets","year":"2019","journal-title":"J Comput Aided Mol Des"},{"issue":"12","key":"10.1016\/j.drudis.2021.09.003_b0195","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1039\/C9MD00347A","article-title":"Dual-target inhibitors of mycobacterial aminoacyl-tRNA synthetases among N-benzylidene-N'-thiazol-2-yl-hydrazines","volume":"10","author":"Kovalenko","year":"2019","journal-title":"Medchemcomm"},{"issue":"9","key":"10.1016\/j.drudis.2021.09.003_b0200","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nchembio.2420","article-title":"A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase","volume":"13","author":"Wellington","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-09642-y","article-title":"Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface","volume":"7","author":"Abrahams","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2021.09.003_b0210","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/pro.3825","article-title":"Allosteric inhibitors of Mycobacterium tuberculosis tryptophan synthase","volume":"29","author":"Michalska","year":"2020","journal-title":"Protein Sci"},{"key":"10.1016\/j.drudis.2021.09.003_b0215","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/07391102.2018.1448303","article-title":"Identification of new benzamide inhibitor against alpha-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations","volume":"37","author":"Naz","year":"2019","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.drudis.2021.09.003_b0220","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mito.2017.01.002","article-title":"Fumarate reductase superfamily: a diverse group of enzymes whose evolution is correlated to the establishment of different metabolic pathways","volume":"34","author":"Jardim-Messeder","year":"2017","journal-title":"Mitochondrion"},{"issue":"3","key":"10.1016\/j.drudis.2021.09.003_b0225","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.chembiol.2017.01.005","article-title":"Fumarase deficiency causes protein and metabolite succination and intoxicates Mycobacterium tuberculosis","volume":"24","author":"Ruecker","year":"2017","journal-title":"Cell Chem Biol"},{"issue":"23","key":"10.1016\/j.drudis.2021.09.003_b0230","doi-asserted-by":"crossref","first-page":"10583","DOI":"10.1021\/acs.jmedchem.9b01716","article-title":"Changing the rules of TB-drug discovery","volume":"62","author":"Harrison","year":"2019","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.drudis.2021.09.003_b0235","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/ja5101257","article-title":"Identification of fumarate hydratase inhibitors with nutrient-dependent cytotoxicity","volume":"137","author":"Takeuchi","year":"2015","journal-title":"J Am Chem Soc"},{"issue":"27","key":"10.1016\/j.drudis.2021.09.003_b0240","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1073\/pnas.1600630113","article-title":"Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory site","volume":"113","author":"Kasbekar","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"10.1016\/j.drudis.2021.09.003_b0245","doi-asserted-by":"crossref","first-page":"10586","DOI":"10.1021\/acs.jmedchem.9b01203","article-title":"Targeting of fumarate hydratase from Mycobacterium tuberculosis using allosteric inhibitors with a dimeric-binding mode","volume":"62","author":"Whitehouse","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2021.09.003_b0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/187152607782110031","article-title":"Targeting iron acquisition by Mycobacterium tuberculosis","volume":"7","author":"Monfeli","year":"2007","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.drudis.2021.09.003_b0255","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/s41598-017-04748-9","article-title":"Virtual screening, pharmacophore development and structure based similarity search to identify inhibitors against IdeR, a transcription factor of Mycobacterium tuberculosis","volume":"7","author":"Rohilla","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.drudis.2021.09.003_b0260","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.drudis.2017.05.005","article-title":"Host-directed therapies offer novel opportunities for the fight against tuberculosis","volume":"22","author":"Machelart","year":"2017","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02777-6","article-title":"Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials","volume":"9","author":"Korbee","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2021.09.003_b0275","doi-asserted-by":"crossref","unstructured":"Matty MA, Knudsen DR, Walton EM, Beerman RW, Cronan MR, Pyle CJ, et al. Potentiation of p2rx7 as a host-directed strategy for control of mycobacterial infection. Elife 2019; 8: e39123. doi:10.7554\/eLife.39123","DOI":"10.7554\/eLife.39123"},{"key":"10.1016\/j.drudis.2021.09.003_b0280","doi-asserted-by":"crossref","unstructured":"Ye L, Chapman TP, Wen Z, Lin L, Qiu Y, Liu Z, et al. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. Aliment Pharmacol Ther 2021; 53: 390\u20139. doi:10.1111\/apt.16130","DOI":"10.1111\/apt.16130"},{"issue":"2","key":"10.1016\/j.drudis.2021.09.003_b0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yexmp.2017.02.008","article-title":"TB-IRIS: proteomic analysis of in vitro PBMC responses to Mycobacterium tuberculosis and response modulation by dexamethasone","volume":"102","author":"Bell","year":"2017","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.drudis.2021.09.003_b0290","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708038","article-title":"An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: implications to a novel combinatorial therapy","volume":"10","author":"Mishra","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.drudis.2021.09.003_b0295","doi-asserted-by":"crossref","first-page":"e1004679","DOI":"10.1371\/journal.ppat.1004679","article-title":"Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment","volume":"11","author":"VanderVen","year":"2015","journal-title":"PLoS Pathog"},{"issue":"6426","key":"10.1016\/j.drudis.2021.09.003_b0300","doi-asserted-by":"crossref","first-page":"eaau8959","DOI":"10.1126\/science.aau8959","article-title":"Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition","volume":"363","author":"Ballinger","year":"2019","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.drudis.2021.09.003_b0305","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/acsinfecdis.6b00150","article-title":"Validation of CoaBC as a bactericidal target in the coenzyme A pathway of Mycobacterium tuberculosis","volume":"2","author":"Evans","year":"2016","journal-title":"ACS Infect Dis"},{"issue":"6239","key":"10.1016\/j.drudis.2021.09.003_b0310","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1126\/science.aaa4690","article-title":"Targeting DnaN for tuberculosis therapy using novel griselimycins","volume":"348","author":"Kling","year":"2015","journal-title":"Science"},{"issue":"7763","key":"10.1016\/j.drudis.2021.09.003_b0315","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41586-019-1315-z","article-title":"Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes","volume":"571","author":"Johnson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.09.003_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.02542","article-title":"Identification of enolase as the target of 2-aminothiazoles in Mycobacterium tuberculosis","volume":"9","author":"Wescott","year":"2018","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.drudis.2021.09.003_b0325","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1021\/acscentsci.5b00212","article-title":"Partial saturation of menaquinone in Mycobacterium tuberculosis: function and essentiality of a novel reductase","volume":"1","author":"Upadhyay","year":"2015","journal-title":"MenJ. ACS Cent Sci"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0330","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02022-16","article-title":"A novel small-molecule inhibitor of the Mycobacterium tuberculosis demethylmenaquinone methyltransferase MenG is bactericidal to both growing and nutritionally deprived persister cells","volume":"8","author":"Sukheja","year":"2017","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.drudis.2021.09.003_b0335","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbapap.2017.11.013","article-title":"Crystal structure of UDP-N-acetylglucosamine-enolpyruvate reductase (MurB) from Mycobacterium tuberculosis","volume":"1866","author":"Eniyan","year":"2018","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"8","key":"10.1016\/j.drudis.2021.09.003_b0340","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/jac\/dkv110","article-title":"Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase","volume":"70","author":"Zhu","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.drudis.2021.09.003_b0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31157-3","article-title":"Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach","volume":"8","author":"Soto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2021.09.003_b0350","doi-asserted-by":"crossref","unstructured":"Freire DM, Gutierrez C, Garza-Garcia A, Grabowska AD, Sala AJ, Ariyachaokun K, et al. An NAD(+) phosphorylase toxin triggers Mycobacterium tuberculosis cell death. Mol Cell 2019; 73: 1282. doi:10.1016\/j.molcel.2019.01.028","DOI":"10.1016\/j.molcel.2019.01.028"},{"key":"10.1016\/j.drudis.2021.09.003_b0355","doi-asserted-by":"crossref","first-page":"fty039","DOI":"10.1093\/femspd\/fty039","article-title":"Toxin-antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis","volume":"76","author":"Slayden","year":"2018","journal-title":"Pathog Dis"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:54:41Z","timestamp":1761224081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621003925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1359644621003925"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.09.003","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}